Title:
神経障害治療に有用な組合せ
Document Type and Number:
Japanese Patent JP2007509898
Kind Code:
A
Abstract:
The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, nontoxic and pharmaceutically acceptable amount of at least one QC-inhibitor, optionally in combination with at least one agent, selected from the group consisting of PEP-inhibitors, inhibitors of DP IV/DP IV-like enzymes, NPY-receptor ligands, NPY agonists, NPY antagonists, ACE-inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases and inhibitors of neutral endopeptidase, to a mammal in need thereof.
Inventors:
Ingos Custin
Stephan still ring
Andre Johannes Niestrology
Hans-Ulrik Demus
Stephen Rossnell
Stephan still ring
Andre Johannes Niestrology
Hans-Ulrik Demus
Stephen Rossnell
Application Number:
JP2006537220A
Publication Date:
April 19, 2007
Filing Date:
October 29, 2004
Export Citation:
Assignee:
Probiodor AG
International Classes:
A61K45/06; A61K31/00; A61K31/166; A61K31/401; A61K31/404; A61K31/4164; A61K31/4184; A61K31/426; A61K31/427; A61K31/428; A61K31/4439; A61K31/4709; A61K31/473; A61K31/498; A61K38/00; A61K38/04; A61P1/14; A61P3/00; A61P5/00; A61P7/00; A61P9/12; A61P25/00; A61P25/02; A61P25/08; A61P25/14; A61P25/16; A61P25/18; A61P25/20; A61P25/22; A61P25/24; A61P25/30; A61P25/32; A61P29/00; A61P43/00; C12N9/99
Domestic Patent References:
| JP2003252795A | 2003-09-10 | |||
| JP2003528150A | 2003-09-24 | |||
| JP2002543815A | 2002-12-24 | |||
| JP2003252795A | 2003-09-10 | |||
| JP2003528150A | 2003-09-24 | |||
| JP2002543815A | 2002-12-24 |
Foreign References:
| WO2004098591A2 | 2004-11-18 | |||
| WO2004098625A2 | 2004-11-18 | |||
| WO2001083472A1 | 2001-11-08 | |||
| WO2002036562A2 | 2002-05-10 |
Other References:
JPN6010059132; 'ＣＨＡＲＡＣＴＥＲＩＺＡＴＩＯＮ ＯＦ ＴＨＥ ＩＮＨＩＢＩＴＩＯＮ ＯＦ ＧＬＵＴＡＭＩＮＹＬ ＣＹＣＬＡＳＥ ＢＹ ＩＭＩＤＡＺＯＬＥ ＤＥＲＩＶＡＴＩＶＥＳ ＡＮＤ ＰＨＥＮＡＮＴＨＲＯＬＩＮＥ' ＥＸＰＥＲＩＭＥＮＴＡＬ ＢＩＯＬＯＧＹ ２００２：Ｍｅｅｔｉｎｇ Ａｂｓｔｒａｃｔｓ Ｖｏｌ．１６， Ｎｏ．４, 2002, Ａ１５７
JPN6010059125; Ｂｉｏｃｈｅｍｉｓｔｒｙ ３３（１）, 1994, １９２-９
JPN6010059127; Ｊ Ｎｅｕｒｏｃｈｅｍ ８４（５）, 200303, ９１９-２９
JPN6010059130; Ｊ Ｐｈａｒｍａｃｏｌ Ｅｘｐ Ｔｈｅｒ ２８８（１）, 1999, ６-１３
JPN6010059125; Ｂｉｏｃｈｅｍｉｓｔｒｙ ３３（１）, 1994, １９２-９
JPN6010059127; Ｊ Ｎｅｕｒｏｃｈｅｍ ８４（５）, 200303, ９１９-２９
JPN6010059130; Ｊ Ｐｈａｒｍａｃｏｌ Ｅｘｐ Ｔｈｅｒ ２８８（１）, 1999, ６-１３
Attorney, Agent or Firm:
Toru Ishikawa